Cara's discovery pipeline includes a number of programs designed to identify first-in-class novel analgesic molecules. Utilizing Cara's discovery technology, DimerScreen™, the Company aims to identify drug candidates which act to regulate GPCR dimer targets present on specific cells involved in regulating pain pathways. This promising, innovative approach provides Cara's researchers with a unique and exciting opportunity to discover novel drugs and drug mechanisms at heretofore unexplored targets.

The support of researchers at the core of this multi-disciplinary research and development program is a key element of Cara's long term growth strategy. At Cara, researchers will find a collaborative and dynamic environment where individual contributions and inventiveness are highly valued.

See current openings